Trial to Compare the Routes of Administration of an Investigational, Personalized, Therapeutic Cancer Vaccine Oncophage (HSPPC-96) in Patients With Metastatic Renal Cell Carcinoma

NCT00082459 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

40

Enrollment

INDUSTRY

Sponsor class

Stopped Lack of enrollment

Conditions

Renal Cell Carcinoma

Interventions

BIOLOGICAL: autologous human tumor-derived HSPPC-96

Sponsor

Agenus Inc.